donepezil has been researched along with Body Weight in 10 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)." | 9.24 | Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017) |
| "Donepezil 23 mg is considered for Alzheimer's disease (AD) to optimize cognitive benefits; however, increased adverse events (AEs) can negatively influence drug adherence." | 7.01 | Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial. ( Han, HJ; Hong, YJ; Kim, HJ; Kim, S; Kwon, M; Lee, JH; Lee, Y; Park, KW; Yang, DW; Youn, YC, 2021) |
| "Obesity is characterized by chronic inflammation of low grade." | 5.56 | Donepezil Prevents Inhibition of Cerebral Energetic Metabolism Without Altering Behavioral Parameters in Animal Model of Obesity. ( Cargnin-Cavalho, A; Costa, AB; da Rosa Turatti, C; de Farias, BX; de Souza Goldim, MP; Engel, NA; Fortunato, JJ; Jeremias, IC; Petronilho, F; Rezin, GT, 2020) |
| "Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)." | 5.24 | Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017) |
| "AchEI therapy has no unfavorable effect on nutritional status or weight in elderly patients with different types of dementia, but it seems that food intake is better in those treated by rivastigmine patch." | 3.83 | Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study. ( Isik, AT; Soysal, P, 2016) |
| "The changes in extracellular acetylcholine levels were investigated by microdialysis in the cortex and hippocampus of aging rats after administration of metrifonate (80 mg/kg), rivastigmine (0." | 3.71 | Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. ( Bellucci, A; Casamenti, F; Costagli, C; Pepeu, G; Scali, C; Schmidt, B, 2002) |
| "Donepezil 23 mg is considered for Alzheimer's disease (AD) to optimize cognitive benefits; however, increased adverse events (AEs) can negatively influence drug adherence." | 3.01 | Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial. ( Han, HJ; Hong, YJ; Kim, HJ; Kim, S; Kwon, M; Lee, JH; Lee, Y; Park, KW; Yang, DW; Youn, YC, 2021) |
| "Safety analyses comprised examination of the incidence, severity, and timing of treatment-emergent adverse events (AEs) and their relationship to treatment initiation; changes in weight, electrocardiogram, vital signs, and laboratory parameters; and the incidence of premature study discontinuation." | 2.76 | Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. ( Bibbiani, F; Brand-Schieber, E; Farlow, M; Hsu, T; Moline, M; Satlin, A; Veloso, F; Yardley, J; Zou, H, 2011) |
| "Obesity is characterized by chronic inflammation of low grade." | 1.56 | Donepezil Prevents Inhibition of Cerebral Energetic Metabolism Without Altering Behavioral Parameters in Animal Model of Obesity. ( Cargnin-Cavalho, A; Costa, AB; da Rosa Turatti, C; de Farias, BX; de Souza Goldim, MP; Engel, NA; Fortunato, JJ; Jeremias, IC; Petronilho, F; Rezin, GT, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, YJ | 1 |
| Han, HJ | 1 |
| Youn, YC | 1 |
| Park, KW | 1 |
| Yang, DW | 1 |
| Kim, S | 1 |
| Kim, HJ | 2 |
| Lee, Y | 1 |
| Kwon, M | 1 |
| Lee, JH | 1 |
| de Farias, BX | 1 |
| Costa, AB | 1 |
| Engel, NA | 1 |
| de Souza Goldim, MP | 1 |
| da Rosa Turatti, C | 1 |
| Cargnin-Cavalho, A | 1 |
| Fortunato, JJ | 1 |
| Petronilho, F | 1 |
| Jeremias, IC | 1 |
| Rezin, GT | 1 |
| Lee, C | 1 |
| Lee, K | 1 |
| Yu, H | 1 |
| Ryu, SH | 1 |
| Moon, SW | 1 |
| Han, C | 1 |
| Lee, JY | 1 |
| Lee, YM | 1 |
| Kim, SG | 1 |
| Kim, KW | 1 |
| Lee, DW | 1 |
| Kim, SY | 1 |
| Lee, SY | 1 |
| Bae, JN | 1 |
| Jung, YE | 1 |
| Kim, JL | 1 |
| Kim, BS | 1 |
| Shin, IS | 1 |
| Kim, YH | 1 |
| Kim, BJ | 1 |
| Kang, HS | 1 |
| Myung, W | 1 |
| Carroll, BJ | 1 |
| Kim, DK | 1 |
| Soysal, P | 1 |
| Isik, AT | 1 |
| Mori, E | 1 |
| Ikeda, M | 1 |
| Nakai, K | 1 |
| Miyagishi, H | 1 |
| Nakagawa, M | 1 |
| Kosaka, K | 1 |
| Agrawal, R | 1 |
| Tyagi, E | 1 |
| Shukla, R | 1 |
| Nath, C | 1 |
| Bhutada, P | 2 |
| Mundhada, Y | 1 |
| Bansod, K | 1 |
| Tawari, S | 1 |
| Patil, S | 1 |
| Dixit, P | 1 |
| Umathe, S | 1 |
| Mundhada, D | 1 |
| Farlow, M | 1 |
| Veloso, F | 1 |
| Moline, M | 1 |
| Yardley, J | 1 |
| Brand-Schieber, E | 1 |
| Bibbiani, F | 1 |
| Zou, H | 1 |
| Hsu, T | 1 |
| Satlin, A | 1 |
| Rahigude, A | 1 |
| Kaulaskar, S | 1 |
| Aswar, M | 1 |
| Otari, K | 1 |
| Scali, C | 1 |
| Casamenti, F | 1 |
| Bellucci, A | 1 |
| Costagli, C | 1 |
| Schmidt, B | 1 |
| Pepeu, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Open-label, Prospective Trial to Evaluate the Safety and Tolerability of Donepezil 23 mg With or Without Intermediate Dose Titration in Patients With Alzheimer's Disease Taking Donepezil Hydrochloride 10 mg[NCT02550665] | Phase 3 | 176 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease[NCT00478205] | Phase 3 | 1,467 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability. (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | -1.2 |
| Donepezil IR 10 mg | -1.2 |
The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment). (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | 0.6 |
| Donepezil IR 10 mg | 0.4 |
The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method. (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Donepezil SR 23 mg | 2.6 |
| Donepezil IR 10 mg | 0.4 |
The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening). (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | 4.23 |
| Donepezil IR 10 mg | 4.29 |
4 trials available for donepezil and Body Weight
| Article | Year |
|---|---|
Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial.
Topics: Alzheimer Disease; Body Weight; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Dr | 2021 |
Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Body Mass Index; Body Weight; Chol | 2017 |
Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies: An exploratory pharmacokinetic/pharmacodynamic analysis in a phase 3 randomized controlled trial.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Cognition; Cytochrome P-450 CYP2D6; Donepezil; | 2016 |
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Body Weight; Cholinesterase Inhibitors; Don | 2011 |
6 other studies available for donepezil and Body Weight
| Article | Year |
|---|---|
Donepezil Prevents Inhibition of Cerebral Energetic Metabolism Without Altering Behavioral Parameters in Animal Model of Obesity.
Topics: Animals; Anti-Obesity Agents; Body Weight; Brain; Diet, High-Fat; Donepezil; Electron Transport Comp | 2020 |
Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Body Mass Index; Body Weight; Cholinesterase | 2016 |
A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia.
Topics: Acetylcholinesterase; Animals; Antibiotics, Antineoplastic; Biomarkers; Blood Glucose; Blotting, Wes | 2009 |
Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes.
Topics: Acetylcholine; Administration, Oral; Analysis of Variance; Animals; Antioxidants; Ascorbic Acid; Ber | 2011 |
Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cholinesterase Inhibitors; Cholinesterases; Diabe | 2012 |
Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats.
Topics: Acetylcholine; Aging; Animals; Body Weight; Brain; Carbamates; Cerebral Cortex; Cholinesterase Inhib | 2002 |